Sanofi (NYSE:SNY)‘s stock had its “neutral” rating restated by J P Morgan Chase & Co in a report released on Thursday.

Several other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Morgan Stanley cut shares of Sanofi from an “overweight” rating to an “underweight” rating in a research report on Friday, December 1st. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Argus reiterated a “buy” rating and set a $55.00 price objective on shares of Sanofi in a research report on Friday, September 1st. Finally, upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. Sanofi has an average rating of “Hold” and a consensus price target of $53.50.

Sanofi (NYSE:SNY) opened at $43.92 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The stock has a market cap of $110,189.91, a P/E ratio of 13.78, a price-to-earnings-growth ratio of 2.60 and a beta of 0.86. Sanofi has a 12-month low of $38.45 and a 12-month high of $50.65.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Fisher Asset Management LLC boosted its stake in shares of Sanofi by 3.3% during the 3rd quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after buying an additional 443,799 shares during the period. Boston Partners boosted its stake in shares of Sanofi by 6.2% during the 3rd quarter. Boston Partners now owns 8,664,983 shares of the company’s stock valued at $431,429,000 after buying an additional 503,799 shares during the period. Hotchkis & Wiley Capital Management LLC boosted its stake in shares of Sanofi by 0.7% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 5,863,945 shares of the company’s stock valued at $291,966,000 after buying an additional 38,597 shares during the period. FMR LLC boosted its stake in shares of Sanofi by 3.0% during the 2nd quarter. FMR LLC now owns 5,374,385 shares of the company’s stock valued at $257,487,000 after buying an additional 155,751 shares during the period. Finally, Macquarie Group Ltd. boosted its stake in shares of Sanofi by 1.1% during the 3rd quarter. Macquarie Group Ltd. now owns 2,622,391 shares of the company’s stock valued at $130,569,000 after buying an additional 29,045 shares during the period. Hedge funds and other institutional investors own 9.09% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Sanofi (SNY) Stock Rating Reaffirmed by J P Morgan Chase & Co” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/sanofi-sny-stock-rating-reaffirmed-by-j-p-morgan-chase-co/1762964.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.